August 2015 | Oncology Live®

August 21, 2015

For oncology specialists, caring for patients with cancer has long meant analyzing the biological and clinical pieces of a puzzle unique to each individual and then figuring out the optimal management plan to meet his or her needs.

August 16, 2015

Recent evidence has shed some light on the prognostic value of microsatellite instability and the potential benefit of checkpoint inhibition in colorectal cancer.

August 14, 2015

Amid continuing excitement over the potential for immunotherapies targeting the PD-1/PD-L1 pathway, two major questions have loomed over PD-L1 expression levels as a biomarker for this emerging new class of drugs.

August 14, 2015

An improved understanding of the natural history of HPV, its interaction with the host immune system, and the distinct molecular alterations underlying HPV-positive cancers, are fueling development of new drugs, particularly immunotherapies geared toward generating an HPV-specific immune response.

August 12, 2015

There is clear evidence that obesity at the time of diagnosis of operable breast cancer is associated with an increased risk of distant recurrence, specifically for HR–positive, HER2-negative disease, and oncologists should consider helping patients better manage their weight as part of their treatment plans.

August 11, 2015

Combining estrogen receptor blockade with targeted cell-cycle inhibitors increases therapeutic options for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer, contributing to an evolving paradigm that is moving new regimens to the forefront of the treatment timeline.

August 07, 2015

The perception that cord blood is an inferior source of stem cells is simply not accurate and may result in delays in lifesaving treatment for patients.

August 05, 2015

Howard A. "Skip" Burris III, MD, has helped launched many widely used anticancer therapies by designing and helping to implement first-in-human studies and by leading advanced clinical trials of promising drugs. He was honored in the Drug Development category with a 2014 Giants of Cancer Care® award.

August 04, 2015

Pierre M. Gholam, MD, discusses managing elderly patients with advanced HCC, including current practices and emerging strategies.

August 04, 2015

A trend in the biomedical industry to bypass the rigors of scientific publishing was highlighted recently in a provocative commentary regarding the virtual absence of data in the peer-reviewed literature demonstrating the utility of a novel proprietary laboratory testing platform.

July 24, 2015

A group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.